AXSM - Axsome Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
New York,
United States
Type: Equity
AXSM price evolution
AXSM
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $315.66 | $331.44 | $386.19 | |
| Short term investments | ||||
| Net receivables | $124.1 | $120.34 | $101.43 | $94.82 |
| Inventory | $14.27 | $15.22 | $15.58 | $15.13 |
| Total current assets | $479.11 | $463.03 | $460.49 | $504.26 |
| Long term investments | ||||
| Property, plant & equipment | $6.41 | $6.79 | $7.22 | $7.62 |
| Goodwill & intangible assets | $62.15 | $63.74 | $65.33 | |
| Total noncurrent assets | $85.2 | $85.24 | $83.97 | |
| Total investments | ||||
| Total assets | $561.46 | $548.23 | $545.73 | $588.24 |
| Current liabilities | ||||
| Accounts payable | $64.25 | $61.34 | $53.79 | $40.68 |
| Deferred revenue | ||||
| Short long term debt | $1.42 | $1.15 | $1.27 | |
| Total current liabilities | $196.19 | $186.57 | $144.05 | $138.85 |
| Long term debt | $182.95 | $189.18 | $187.64 | $185.1 |
| Total noncurrent liabilities | $258.8 | $257.64 | $258.4 | |
| Total debt | $190.6 | $188.8 | $186.37 | |
| Total liabilities | $468.56 | $445.37 | $401.69 | $397.26 |
| Shareholders' equity | ||||
| Retained earnings | -$1047.88 | -$983.27 | -$903.93 | -$835.57 |
| Other shareholder equity | ||||
| Total shareholder equity | $102.85 | $144.04 | $190.98 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $386.19 | $200.84 | $86.47 | $183.88 |
| Short term investments | ||||
| Net receivables | $94.82 | $37.7 | ||
| Inventory | $15.13 | $4.32 | ||
| Total current assets | $504.26 | $245.64 | $86.52 | $184.02 |
| Long term investments | ||||
| Property, plant & equipment | $7.62 | $1.14 | $0.94 | $1.79 |
| Goodwill & intangible assets | $65.33 | $69.97 | ||
| Total noncurrent assets | $83.97 | $85.83 | $1.27 | $2.11 |
| Total investments | ||||
| Total assets | $588.24 | $331.48 | $87.79 | $186.13 |
| Current liabilities | ||||
| Accounts payable | $40.68 | $38.61 | $13.15 | $13.5 |
| Deferred revenue | ||||
| Short long term debt | $1.27 | $0.42 | $0.62 | $1.22 |
| Total current liabilities | $138.85 | $96.56 | $23.07 | $23.44 |
| Long term debt | $185.1 | $94.26 | $49.09 | $48.9 |
| Total noncurrent liabilities | $258.4 | $125.36 | $49.09 | $48.9 |
| Total debt | $186.37 | $94.68 | $49.71 | $50.12 |
| Total liabilities | $397.26 | $221.92 | $72.15 | $72.34 |
| Shareholders' equity | ||||
| Retained earnings | -$835.57 | -$596.33 | -$409.2 | -$278.8 |
| Other shareholder equity | ||||
| Total shareholder equity | $190.98 | $109.56 | $15.63 | $113.79 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $104.76 | $87.17 | $75 | $71.53 |
| Cost of revenue | $8.05 | $6.3 | $7.38 | |
| Gross Profit | $96.33 | $79.11 | $68.7 | $64.15 |
| Operating activities | ||||
| Research & development | $49.85 | $36.83 | $30.8 | |
| Selling, general & administrative | $103.55 | $98.97 | $86.81 | |
| Total operating expenses | $158.95 | $157.16 | $135.98 | $162.43 |
| Operating income | -$78.05 | -$67.28 | -$98.27 | |
| Income from continuing operations | ||||
| EBIT | -$78.05 | -$67.28 | -$98.27 | |
| Income tax expense | -$0.33 | |||
| Interest expense | -$1.98 | $1.3 | $1.08 | $0.7 |
| Net income | ||||
| Net income | -$64.6 | -$79.34 | -$68.36 | -$98.65 |
| Income (for common shares) | -$79.34 | -$68.36 | -$98.65 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $270.6 | $50.04 | ||
| Cost of revenue | $26.07 | $5.2 | ||
| Gross Profit | $244.53 | $44.84 | ||
| Operating activities | ||||
| Research & development | $97.94 | $57.95 | $58.06 | $70.24 |
| Selling, general & administrative | $323.12 | $159.25 | $66.65 | $28.9 |
| Total operating expenses | $476.36 | $224.64 | $124.71 | $99.14 |
| Operating income | -$231.82 | -$179.8 | -$124.71 | -$99.14 |
| Income from continuing operations | ||||
| EBIT | -$231.82 | -$179.8 | -$124.71 | -$100.39 |
| Income tax expense | $0.96 | -$0.05 | ||
| Interest expense | $6.45 | $7.33 | $5.7 | $2.57 |
| Net income | ||||
| Net income | -$239.24 | -$187.13 | -$130.4 | -$102.9 |
| Income (for common shares) | -$239.24 | -$187.13 | -$130.4 | -$102.9 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$79.34 | -$68.36 | -$98.65 | |
| Operating activities | ||||
| Depreciation | $2.33 | $2.19 | $2.08 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $21.38 | $20.19 | $18.91 | |
| Total cash flows from operations | -$30.11 | -$53.47 | -$30.36 | |
| Investing activities | ||||
| Capital expenditures | -$0.05 | -$0.1 | -$0.01 | |
| Investments | ||||
| Total cash flows from investing | -$0.24 | -$0.05 | -$0.1 | -$0.01 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $18 | $2.5 | $1.15 | |
| Net borrowings | -$0.19 | -$0.16 | $0.85 | |
| Total cash flows from financing | $43.6 | $14.38 | -$1.19 | -$0 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$58.85 | -$15.78 | -$54.75 | -$30.37 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$239.24 | -$187.13 | -$130.4 | -$102.9 |
| Operating activities | ||||
| Depreciation | $8.28 | $5.56 | $1.16 | $0.08 |
| Business acquisitions & disposals | -$53 | |||
| Stock-based compensation | $62.62 | $37.73 | $20.8 | $14.76 |
| Total cash flows from operations | -$145.08 | -$116.51 | -$108.23 | -$78.46 |
| Investing activities | ||||
| Capital expenditures | -$0.58 | -$0.7 | -$0.31 | -$0.05 |
| Investments | ||||
| Total cash flows from investing | -$0.58 | -$53.7 | -$0.31 | -$0.05 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $271.17 | $243.04 | $11.61 | $15.18 |
| Net borrowings | $83.56 | $44.51 | -$0.31 | $27.24 |
| Total cash flows from financing | $331.01 | $284.58 | $11.13 | $42.41 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $185.35 | $114.37 | -$97.4 | -$36.09 |
News
Fundamentals
| Market cap | $4.95B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 48.44M |
| Revenue | $338.46M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$310.95M |
| Revenue Q/Q | 81.27% |
| Revenue Y/Y | 51.47% |
| P/E ratio | -15.93 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 14.64 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$6.42 |
|---|---|
| ROA | -55.44% |
| ROE | N/A |
| Debt/Equity | 2.08 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.44 |
| Quick ratio | 2.37 |